G2A and LPC: Regulatory functions in immunity

Prostaglandins and Other Lipid Mediators

Volumn 89, Issue 3-4, 2009, Pages 73-81

  Kabarowski, Janusz H ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Autoimmunity; Chronic inflammatory disease; G2A receptor; Immunity; Inflammation; Lysophosphatidylcholine

Indexed keywords

CHOLESTEROL; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR G2A; LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL GROWTH; CELL PROLIFERATION; CHEMOTAXIS; CHOLESTEROL METABOLISM; GENOTOXICITY; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; LIPOPROTEIN METABOLISM; MACROPHAGE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL CYCLE PROTEINS; CHEMOTAXIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; IMMUNITY, INNATE; LEUKOCYTES; LIGANDS; LYSOPHOSPHATIDYLCHOLINES; MACROPHAGES; RECEPTORS, G-PROTEIN-COUPLED; SEPSIS; SIGNAL TRANSDUCTION;

EID: 69549108246     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.04.007     Document Type: Review

References (84)

1. Wiesner P., Leidl K., Boettcher A., Schmitz G., and Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 50 (2009) 574-585
2. Lands W.E., and Samuelsson B. Phospholipid precursors of prostaglandins. Biochim Biophys Acta 164 (1968) 426-429
3. Jackson S.K., Abate W., and Tonks A.J. Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery. Pharmacol Ther 119 (2008) 104-114
4. Murakami M., and Kudo I. Secretory phospholipase A2. Biol Pharm Bull 27 (2004) 1158-1164
5. Memon R.A., Staprans I., Noor M., et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20 (2000) 1536-1542
6. Matsumoto T., Kobayashi T., and Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 14 (2007) 3209-3220
7. Wu R., Svenungsson E., Gunnarsson I., et al. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus 8 (1999) 142-150
8. Kurien B.T., and Scofield R.H. Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 44 (2006) 349-356
9. Fuchs B., Schiller J., Wagner U., Hantzschel H., and Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by (31)P NMR and MALDI-TOF MS. Clin Biochem 38 (2005) 925-933
10. Yang L.V., Radu C.G., Wang L., Riedinger M., and Witte O.N. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 105 (2004) 1127-1134
11. Radu C.G., Yang L.V., Riedinger M., Au M., and Witte O.N. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc Natl Acad Sci USA 101 (2004) 245-250
12. Yan J.J., Jung J.S., Lee J.E., et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10 (2004) 161-167
13. Frasch S.C., Zemski-Berry K., Murphy R.C., Borregaard N., Henson P.M., and Bratton D.L. Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol 178 (2007) 6540-6548
14. Frasch S.C., Berry K.Z., Fernandez-Boyanapalli R., et al. NADPH oxidase-dependent generation of lysophosphatidylserine enhances clearance of activated and dying neutrophils via G2A. J Biol Chem 283 (2008) 33736-33749
15. Chen G., Li J., Qiang X., et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46 (2005) 623-627
16. Peter C., Waibel M., Radu C.G., et al. Migration to apoptotic "find-me" signals is mediated via the phagocyte receptor G2A. J Biol Chem 283 (2008) 5296-5305
17. Weng Z., Fluckiger A.C., Nisitani S., et al. A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc Natl Acad Sci USA 95 (1998) 12334-12339
18. Zohn I.E., Klinger M., Karp X., et al. G2A is an oncogenic G protein-coupled receptor. Oncogene 19 (2000) 3866-3877
19. Kabarowski J.H., Feramisco J.D., Le L.Q., et al. Direct genetic demonstration of G alpha 13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent actin rearrangement. Proc Natl Acad Sci USA 97 (2000) 12109-12114
20. Le L.Q., Kabarowski J.H., Weng Z., et al. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14 (2001) 561-571
21. Osmers I., Smith S.S., Parks B.W., et al. Deletion of the G2A receptor fails to attenuate experimental autoimmune encephalomyelitis. J Neuroimmunol 207 (2009) 18-23
22. Le L.Q., Kabarowski J.H., Wong S., Nguyen K., Gambhir S.S., and Witte O.N. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell 1 (2002) 381-391
23. Kabarowski J.H., Zhu K., Le L.Q., Witte O.N., and Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293 (2001) 702-705
24. Lin P., and Ye R.D. The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis. J Biol Chem 278 (2003) 14379-14386
25. Parks B.W., Gambill G.P., Lusis A.J., and Kabarowski J.H. Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low-density lipoprotein receptor-deficient mice. J Lipid Res 46 (2005) 1405-1415
26. Bolick D.T., Skaflen M.D., Johnson L.E., et al. G2A deficiency in mice promotes macrophage activation and atherosclerosis. Circ Res 104 (2009) 318-327
27. Parks B.W., Lusis A.J., and Kabarowski J.H. Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 26 (2006) 2703-2709
28. Parks B.W., Srivastava R., Yu S., and Kabarowski J.H. ApoE-dependent modulation of HDL and atherosclerosis by G2A in LDL receptor-deficient mice independent of bone marrow-derived cells. Arterioscler Thromb Vasc Biol 29 (2009) 539-547
29. Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., and Chen C.J. Lysophosphatidylcholine and secretory phospholipase A(2) in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 12 (2006) RA5-16
30. Pruzanski W., Lambeau L., Lazdunsky M., Cho W., Kopilov J., and Kuksis A. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta 1736 (2005) 38-50
31. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85 (1988) 2805-2809
32. Jing Q., Xin S.M., Zhang W.B., Wang P., Qin Y.W., and Pei G. Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ Res 87 (2000) 52-59
33. Ikeno Y., Konno N., Cheon S.H., et al. Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem 280 (2005) 28044-28052
34. Obinata H., and Izumi T. G2A as a receptor for oxidized free fatty acids. Prostaglandins Other Lipid Mediat (2008)
35. Obinata H., Hattori T., Nakane S., Tatei K., and Izumi T. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem 280 (2005) 40676-40683
36. Yin H., Chu A., Li W., et al. Lipid G protein-coupled receptor ligand identification using {beta}-arrestin pathhunter TM assay. J. Biol. Chem. 284 (2009) 12328-12338
37. Hattori T., Obinata H., Ogawa A., et al. G2A plays proinflammatory roles in human keratinocytes under oxidative stress as a receptor for 9-hydroxyoctadecadienoic acid. J Invest Dermatol 128 (2008) 1123-1133
38. Witte O.N., Kabarowski J.H., Xu Y., Le L.Q., and Zhu K. Retraction. Science 307 (2005) 206
39. Soga T., Ohishi T., Matsui T., et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 326 (2005) 744-751
40. Wang L., Radu C.G., Yang L.V., Bentolila L.A., Riedinger M., and Witte O.N. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol Biol Cell 16 (2005) 2234-2247
41. Han K.H., Hong K.H., Ko J., et al. Lysophosphatidylcholine up-regulates CXCR4 chemokine receptor expression in human CD4 T cells. J Leukoc Biol 76 (2004) 195-202
42. Zernecke A., Shagdarsuren E., and Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28 (2008) 1897-1908
43. Randolph G.J. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol 19 (2008) 462-468
44. Steinman R.M., Turley S., Mellman I., and Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191 (2000) 411-416
45. Kim Y.L., Im Y.J., Ha N.C., and Im D.S. Albumin inhibits cytotoxic activity of lysophosphatidylcholine by direct binding. Prostaglandins Other Lipid Mediat 83 (2007) 130-138
46. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
47. Ojala P.J., Hermansson M., Tolvanen M., et al. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 45 (2006) 14021-14031
48. Lin P., Welch E.J., Gao X.P., Malik A.B., and Ye R.D. Lysophosphatidylcholine modulates neutrophil oxidant production through elevation of cyclic AMP. J Immunol 174 (2005) 2981-2989
49. Wang H., Li W., Goldstein R., Tracey K.J., and Sama A.E. HMGB1 as a potential therapeutic target. Novartis Found Symp 280 (2007) 73-85 [discussion 85-91, 160-4]
50. Yang H., Ochani M., Li J., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101 (2004) 296-301
51. Ulloa L., Ochani M., Yang H., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 99 (2002) 12351-12356
52. Witztum J.L., and Berliner J.A. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 9 (1998) 441-448
53. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
54. Parthasarathy S., and Barnett J. Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B-100. Proc Natl Acad Sci USA 87 (1990) 9741-9745
55. Timmins J.M., Lee J.Y., Boudyguina E., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115 (2005) 1333-1342
56. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
57. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
58. Wells I.C., Peitzmeier G., and Vincent J.K. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol 45 (1986) 303-310
59. Pinto F., Brenner T., Dan P., Krimsky M., and Yedgar S. Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. Glia 44 (2003) 275-282
60. Kalyvas A., and David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41 (2004) 323-335
61. Koh J.S., and Levine J.S. Apoptosis and autoimmunity. Curr Opin Nephrol Hypertens 6 (1997) 259-266
62. Aprahamian T., Rifkin I., Bonegio R., et al. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 199 (2004) 1121-1131
63. Chou M.Y., Hartvigsen K., Hansen L.F., et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 263 (2008) 479-488
64. Kim S.J., Gershov D., Ma X., Brot N., and Elkon K.B. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 196 (2002) 655-665
65. Peng Y., Kowalewski R., Kim S., and Elkon K.B. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol 42 (2005) 781-787
66. Fu M., Fan P.S., Li W., et al. Identification of poly-reactive natural IgM antibody that recognizes late apoptotic cells and promotes phagocytosis of the cells. Apoptosis 12 (2007) 355-362
67. Lauber K., Bohn E., Krober S.M., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113 (2003) 717-730
68. Gude D.R., Alvarez S.E., Paugh S.W., et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J 22 (2008) 2629-2638
69. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45 (2004) 1169-1196
70. Pruzanski W., Stefanski E., de Beer F.C., de Beer M.C., Ravandi A., and Kuksis A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 41 (2000) 1035-1047
71. Perrin-Cocon L., Agaugue S., Coutant F., et al. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses. Vaccine 24 (2006) 1254-1263
72. Stanic A.K., Stein C.M., Morgan A.C., et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci USA 103 (2006) 7018-7023
73. Forte T.M., Subbanagounder G., Berliner J.A., et al. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 43 (2002) 477-485
74. Huang J.H., Cardenas-Navia L.I., Caldwell C.C., et al. Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol 178 (2007) 7747-7755
75. Burger D., and Dayer J.M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev 1 (2002) 111-117
76. McMahon M., Grossman J., FitzGerald J., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 (2006) 2541-2549
77. Dinu A.R., Merrill J.T., Shen C., Antonov I.V., Myones B.L., and Lahita R.G. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7 (1998) 355-360
78. Batuca J.R., Ames P.R., Isenberg D.A., and Alves J.D. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann NY Acad Sci 1108 (2007) 137-146
79. Batuca J.R., Ames P.R., Amaral M., Favas C., Isenberg D.A., and Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 48 (2009) 26-31
80. Hyka N., Dayer J.M., Modoux C., et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97 (2001) 2381-2389
81. Kiss E., Seres I., Tarr T., Kocsis Z., Szegedi G., and Paragh G. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann NY Acad Sci 1108 (2007) 83-91
82. Wilhelm AJ, Zabalawi M, Grayson JM, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol; 2009 [E-pub ahead of print].
83. van Meeteren L.A., and Moolenaar W.H. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46 (2007) 145-160
84. Soupene E., Fyrst H., and Kuypers F.A. Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes. Proc Natl Acad Sci USA 105 (2008) 88-93